6 results on '"Fondazione Cariverona"'
Search Results
2. SCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALY
- Author
-
FONDAZIONE CARIVERONA, Azienda ULSS di Verona e Provincia, and Carlo Catassi, M.D., PROFESSOR OF PEDIATRICS AND HEAD OF THE DEPARTMENT OF PEDIATRICS, UNIVERSITA POLITECNICA DELLE MARCHE
- Published
- 2021
3. Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses (PHYSICO-DSM-VR)
- Author
-
FONDAZIONE CARIVERONA, Universita di Verona, and Lorenzo Burti, Professor
- Published
- 2016
4. Chemical conjugation of ΔF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions
- Author
-
Giulio Cabrini, Marco Colombatti, Luigi Cattel, Franco Dosio, Federica Quiri, Caroline Norez, Anna Tamanini, Paolo Rizzotti, Erika Barison, Matteo Pasetto, Cristina Anselmi, Maria Cristina Dechecchi, Institut de physiologie et biologie cellulaires (IPBC), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Laboratory of Molecular Pathology, University Hospital of Verona, Department of Pathology, University of Verona (UNIVR), Department of Science and Technology of Medicines, University of Turin, and This work was partially supported by grants from Fondazione Cariverona (Progetti Bando 2004), by MIUR (PRIN 2005), and by Italian Cystic Fibrosis Research Foundation (#1/2006) (to M. Colombatti), and Fondazione Cariverona-Bando 2005-Malattie rare e della povertà (to G. Cabrini).
- Subjects
Protein Folding ,Physiology ,medicine.disease_cause ,Cystic fibrosis ,Guanidines ,0302 clinical medicine ,Fibrosis ,Disulfides ,Intracellular activation ,0303 health sciences ,Mutation ,Drug Carriers ,biology ,respiratory system ,Human serum albumin ,Transmembrane protein ,Cystic fibrosis transmembrane conductance regulator ,Cell biology ,Transport protein ,Cross-Linking Reagents ,Biochemistry ,030220 oncology & carcinogenesis ,Oxidoreductases ,Immunosuppressive Agents ,medicine.drug ,Pulmonary and Respiratory Medicine ,conjugates ,Correctors ,congenital, hereditary, and neonatal diseases and abnormalities ,Serum albumin ,Cell Line ,03 medical and health sciences ,Physiology (medical) ,medicine ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Humans ,Point Mutation ,chaperones ,Serum Albumin ,030304 developmental biology ,Correctors, Cystic fibrosis, Cystic fibrosis transmembrane conductance regulator, Intracellular activation, Transporter protein ,Cell Biology ,medicine.disease ,cystic fibrosis ,transporter protein ,intracellular activation ,Transporter protein ,digestive system diseases ,respiratory tract diseases ,biology.protein ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Molecular Chaperones - Abstract
(IF : 4,214); International audience; The most common mutation of the cystic fibrosis (CF) gene, the deletion of Phe508, encodes a protein (DeltaF508-CFTR) that fails to fold properly, thus mutated DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) is recognized and degraded via the ubiquitin-proteasome endoplasmic reticulum-associated degradation pathway. Chemical and pharmacological chaperones and ligand-induced transport open options for designing specific drugs to control protein (mis)folding or transport. A class of compounds that has been proposed as having potential utility in DeltaF508-CFTR is that which targets the molecular chaperone and proteasome systems. In this study, we have selected deoxyspergualin (DSG) as a reference molecule for this class of compounds and for ease of cross-linking to human serum albumin (HSA) as a protein transporter. Chemical cross-linking of DSG to HSA via a disulfide-based cross-linker and its administration to cells carrying DeltaF508-CFTR resulted in a greater enhancement of DeltaF508-CFTR function than when free DSG was used. Function of the selenium-dependent oxidoreductase system was required to allow intracellular activation of HSA-DSG conjugates. The principle that carrier proteins can deliver pharmacological chaperones to cells leading to correction of defective CFTR functions is therefore proven and warrants further investigations.
- Published
- 2008
- Full Text
- View/download PDF
5. Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
- Author
-
Pietro Delfino, Paul Takam Kamga, Adriana Cassaro, Annalisa Adamo, Giada Dal Collo, Mauro Krampera, Carmine Carbone, Massimiliano Bonifacio, Alice Bonato, Riccardo Bazzoni, Ilaria Tanasi, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Stem Cell Research Laboratory, University of Verona (UNIVR), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Niguarda Hospital [Milan, Italy], University of Milan, University and Hospital Trust of Verona, Fondazione 'Policlinico Universitario A. Gemelli' [Rome], Funding: This work was supported by: (i) Progetti di Rilevante Interesse Nazionale (PRIN) Italia, Bando 2017, (ii) Fondazione CARIVERONA Italia, Bando 2012., and Immunology
- Subjects
0301 basic medicine ,Cancer Research ,Stromal cell ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,lcsh:RC254-282 ,Article ,drug target ,03 medical and health sciences ,Wnt ,0302 clinical medicine ,AML ,In vivo ,medicine ,Niclosamide ,business.industry ,Wnt signaling pathway ,Myeloid leukemia ,LRP6 ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,microenvironment ,In vitro ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Bone marrow ,business ,medicine.drug - Abstract
Wnt/&beta, catenin signaling has been reported in Acute Myeloid leukemia, but little is known about its significance as a prognostic biomarker and drug target. In this study, we first evaluated the correlation between expression levels of Wnt molecules and clinical outcome. Then, we studied&mdash, in vitro and in vivo&mdash, the anti-leukemic value of combinatorial treatment between Wnt inhibitors and classic anti-leukemia drugs. Higher levels of &beta, catenin, Ser675-phospho-&beta, catenin and GSK-3&alpha, (total and Ser 9) were found in AML cells from intermediate or poor risk patients, nevertheless, patients presenting high activity of Wnt/&beta, catenin displayed shorter progression-free survival (PFS) according to univariate analysis. In vitro, many pharmacological inhibitors of Wnt signalling, i.e., LRP6 (Niclosamide), GSK-3 (LiCl, AR-A014418), and TCF/LEF (PNU-74654) but not Porcupine (IWP-2), significantly reduced proliferation and improved the drug sensitivity of AML cells cultured alone or in the presence of bone marrow stromal cells. In vivo, PNU-74654, Niclosamide and LiCl administration significantly reduced the bone marrow leukemic burden acting synergistically with Ara-C, thus improving mouse survival. Overall, our study demonstrates the antileukemic role of Wnt/&beta, catenin inhibition that may represent a potential new therapeutics strategy in AML.
- Published
- 2020
- Full Text
- View/download PDF
6. HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development
- Author
-
Annalisa Adamo, Pietro Delfino, Alessandro Gatti, Alice Bonato, Paul Takam Kamga, Riccardo Bazzoni, Stefano Ugel, Angela Mercuri, Simone Caligola, Mauro Krampera, University of Verona (UNIVR), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona Università degli Studi di Verona, and This study was in part performed in the LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University of Verona. Funding. This work was supported by Fondazione Cariverona.
- Subjects
0301 basic medicine ,Stromal cell ,[SDV]Life Sciences [q-bio] ,stromal cell lines ,Context (language use) ,Biology ,immunomodulation ,Cell and Developmental Biology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,medicine ,lcsh:QH301-705.5 ,Original Research ,tumor biology ,Mesenchymal stem cell ,tumor escape ,Cell Biology ,030104 developmental biology ,medicine.anatomical_structure ,lcsh:Biology (General) ,Tumor Escape ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,Bone marrow ,mesenchymal stromal cells ,Immortalised cell line ,Developmental Biology - Abstract
International audience; In this study, we compared the overall gene and pathway expression profiles of HS-5 and HS-27A stromal cell lines with those of primary bone marrow MSCs to verify if they can be considered a reliable alternative tool for evaluating the contribution of MSCs in tumor development and immunomodulation. Indeed, due to their easier manipulation in vitro as compared to primary MSC cultures, several published studies took advantage of stromal cell lines to assess the biological mechanisms mediated by stromal cells in influencing tumor biology and immune responses. However, the process carried out to obtain immortalized cell lines could profoundly alter gene expression profile, and consequently their biological characteristics, leading to debatable results. Here, we evaluated the still undisclosed similarities and differences between HS-5, HS-27A cell lines and primary bone marrow MSCs in the context of tumor development and immunomodulation. Furthermore, we assessed by standardized immunological assays the capability of the cell lines to reproduce the general mechanisms of MSC immunoregulation. We found that only HS-5 cell line could be suitable to reproduce not only the MSC capacity to influence tumor biology, but also to evaluate the molecular mechanisms underlying tumor immune escape mediated by stroma cells. However, HS-5 pre-treatment with inflammatory cytokines, that normally enhances the immunosuppressive activity of primary MSCs, did not reproduce the same MSCs behavior, highlighting the necessity to accurately set up in vitro assays when HS-5 cell line is used instead of its primary counterpart.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.